

Use of bevacizumab as an additional strategy in angle closure glaucoma – case report

Joanna Liput and Iwona Helemejko

Department of Ophthalmology, Wrocław Medical University, Poland

We report the use of bevacizumab (Avastin) as an additional strategy in angle closure glaucoma based on the case of 47 years old male qualified to cataract removal as anti-glaucoma procedure in whom we observed iris and lens neovascularization. As a first step we administered 1.25 mg of bevacizumab into the anterior chamber. Iris as well as lens neovascularization completely disappeared 48 hours later. Finally after lens removal we achieved deeper anterior chamber, reduction and stabilization of intraocular pressure without necessity of hypotensive agent's administration and improvement of visual acuity.

Biography

Joanna Liput has completed postdoctoral studies and her Ph.D at the age of 29 years from Wrocław Medical University, Poland. She has published more than 25 papers in national and international journals. In 2006 granted by European Board of Ophthalmology. Currently works at Great Western Hospital in Swindon, UK.

jjliput@op.pl